Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $23.52M
• Dividend Yield: 11.14%
• Average Volume (3M): 4.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.21
• Revenue Growth: -0.29%
• EPS Growth: 94.56%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.46
• Shares Outstanding: 8,055,150
• 10 Day Avg. Volume: 4,683
• 30 Day Avg. Volume: 4,066
• PEG Ratio: 0.02
• Price to Book (P/B): -1.73
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 6.12
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 0.84
• Enterprise Value/Gross Profit: 1.09
• Enterprise Value/Ebitda: 54.95
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.42
• Revenue Forecast (FY): $29.90M

• Rating: 43 Neutral
• Price Target: $3.00 ▼(-26.65% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is weighed down primarily by weak financial quality (sharp recent revenue contraction, earnings volatility, and negative equity) and bearish technical signals (below key moving averages with negative MACD). A very high dividend yield provides some support, but is tempered by loss-making results and elevated risk highlighted by the NYSE American compliance notice.

Positive Factors

Cash Generation Resilience

Consistent positive operating cash flow across reported years shows the core business generates real cash despite accounting losses. That cashability supports ongoing storage operations, funds short-term obligations and gives management runway to execute a compliance plan without immediate external financing, though coverage remains modest.

High Gross Margins

Sustained gross margins near the 70% range indicate attractive unit economics for cord blood/tissue processing and storage. High margins provide structural leverage to operating expenses as volumes recover, enabling faster recovery to profitability if top-line stabilizes and supporting long-term margin sustainability in a service-oriented biobanking model.

Recurring Revenue Model

The business earns recurring annual storage fees and upfront processing fees, creating predictable lifetime revenue per client. This subscription-like cash flow supports long-term visibility, retention-driven economics via hospital/physician channels, and steadier revenue even amid lumpy new-client cycles.

Negative Factors

Negative Equity & Listing Risk

Persistently negative stockholders' equity materially weakens the balance sheet and constrains financial flexibility. The NYSE American compliance notice creates a concrete delisting risk and forces management to prioritize recapitalization or restructuring, which could dilute shareholders or limit strategic investments over the next 12–18 months.

Sharp Revenue Decline

A ~57% year-over-year revenue collapse is a structural red flag for demand, distribution or operational execution. Such a drop reduces scale economies, strains margin absorption and cash conversion, and makes it harder to cover fixed costs tied to lab and storage facilities, potentially prolonging recovery and impeding reinvestment.

Profitability Volatility

Wide swings between profit and loss across recent years indicate inconsistent earnings power and potential exposure to nonrecurring charges or volume-sensitive costs. This volatility undermines planning, threatens dividend sustainability, and raises the probability management must take structural cost or financing actions that could impair long-term growth.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International (CCEL) is a leading biotechnology company specializing in the collection, processing, and storage of stem cells derived from umbilical cord blood and tissue. Founded in 1992, CCEL operates primarily in the regenerative medicine sector, offering services that cater to families looking to preserve their newborn's stem cells for potential future medical use. The company's core offerings include private and public cord blood banking, as well as tissue banking services, which are critical for various therapeutic applications and research.

How the Company Makes Money

Cryo-Cell primarily makes money by charging customers for newborn stem cell banking services and related fees over the life of a storage contract. Key revenue streams typically include: (1) upfront service fees for the collection kit and laboratory processing of cord blood and/or cord tissue after a birth; (2) recurring storage fees (often annual) for maintaining cryopreserved specimens in long-term storage; and (3) other biobanking- or laboratory-related service revenues associated with its cell processing and storage infrastructure (specific line-item details depend on the company’s public reporting). The company’s earnings are supported by its ability to acquire new banking clients (often through physician/OB-GYN channels and birth-hospital workflows), retain existing clients who continue paying recurring storage fees, and operate compliant laboratory and storage facilities that enable long-duration contracts. Specific named partnerships, contract structures, pricing, and segment revenue breakdowns: null.

Cryo-Cell International Financial Statement Overview

Summary

Overall fundamentals are mixed: cash flow is generally positive (a relative strength), but revenue fell sharply in the latest year, profitability is volatile with recent losses, and the balance sheet is a major concern due to persistently negative stockholders’ equity.

Income Statement

Revenue has been broadly flat over the last several years, with a sharp decline in the most recent annual period (down ~57% year over year). Profitability is volatile: strong gross margins (roughly 69–77%) suggest a favorable core service mix, but operating results swung from solid profits in 2020–2022 to a large loss in 2023, a modest profit in 2024, and back to a net loss in 2025. The latest period also shows negative EBITDA and negative net margin, indicating cost pressure and/or non-recurring charges overwhelming an otherwise strong gross profit profile.

Balance Sheet

The balance sheet is the key weak spot. Stockholders’ equity is negative in most years (and materially negative in the latest period), which reduces financial flexibility and makes leverage signals harder to interpret. Total debt fluctuated significantly (peaking in 2024 and declining in 2025), but the presence of negative equity elevates risk despite the lower absolute debt level in the latest year. Overall, assets are sizable, but the consistently weak equity position is a meaningful constraint.

Cash Flow

Cash generation is a relative strength: operating cash flow is positive in every year provided, including the latest period, and free cash flow is positive in most years (with a large outflow in 2022). In the most recent year, free cash flow remained solid and closely tracked net income despite reported losses, indicating non-cash charges and/or working-capital support to cash results. However, free cash flow growth is highly volatile, and cash flow coverage versus obligations appears modest, suggesting resilience but not a wide margin of safety.

Breakdown	Nov 2025	Feb 2025	Nov 2023	Feb 2023	Nov 2021
Income Statement
Total Revenue	31.57M	31.99M	31.34M	30.34M	28.88M
Gross Profit	24.19M	24.04M	22.90M	21.54M	19.90M
EBITDA	480.58K	1.42M	-10.42M	6.65M	5.32M
Net Income	-2.43M	402.10K	-9.52M	2.77M	2.08M
Balance Sheet
Total Assets	61.73M	64.68M	61.22M	64.89M	60.66M
Cash, Cash Equivalents and Short-Term Investments	3.30M	3.50M	980.25K	1.72M	8.34M
Total Debt	3.20M	12.93M	10.90M	11.61M	2.82M
Total Liabilities	80.33M	77.89M	72.25M	66.41M	56.48M
Stockholders Equity	-18.61M	-13.22M	-11.03M	-1.52M	4.18M
Cash Flow
Free Cash Flow	5.25M	3.61M	1.28M	-8.60M	974.92K
Operating Cash Flow	5.48M	6.01M	8.92M	8.57M	7.93M
Investing Cash Flow	-975.33K	-4.88M	-8.14M	-15.28M	-6.95M
Financing Cash Flow	-4.75M	-979.12K	-2.07M	147.86K	-3.07M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.09 is above the 20-day moving average (MA) of 3.29, above the 50-day MA of 3.37, and below the 200-day MA of 4.26, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 18.79 is Positive, neither overbought nor oversold. The STOCH value of 2.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.86M	-271.02	-8.75%	―	17.84%	-156.13%
DCGO	47 Neutral	$64.28M	-1.23	-17.22%	―	-47.03%	-274.41%
CCM	44 Neutral	$16.76M	-0.11	―	―	-22.38%	56.66%
CCEL	43 Neutral	$23.52M	-13.22	15.27%	11.14%	-0.29%	94.56%
PIII	43 Neutral	$22.77M	-0.23	-257.39%	―	-2.15%	-6.72%

Cryo-Cell International Corporate Events

Cryo-Cell Faces NYSE American Listing Compliance Challenges

On March 9, 2026, Cryo-Cell International, Inc. received notice from NYSE American that it was not in compliance with continued listing standards due to a stockholders’ deficit as of Nov. 30, 2025 and net losses in two of its three most recent fiscal years. The company disclosed the notice in a March 12, 2026 press release and said its shares will continue to trade under the CCEL ticker while it works on a plan to regain compliance.

Cryo-Cell intends to submit a compliance plan by April 8, 2026, after which NYSE American may grant up to 18 months for the company to restore compliance, during which the stock remains listed if other requirements are met. The company cautioned that there is no assurance its plan will be accepted or that it will meet the standards in time, leaving investors exposed to the risk of potential delisting if compliance cannot be reestablished.

The most recent analyst rating on (CCEL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.